Genentech cut 348 employees at its South San Francisco headquarters in 2025 across three waves. Here is what your biotech and oncology expertise is worth independently.

Genentech laid off 348 employees at its South San Francisco headquarters across three rounds in 2025: 143 in May, 87 in July, and 118 more effective November 28. The cuts reflect the ongoing restructuring of Genentech's parent company Roche, which has been managing a more selective R&D portfolio and rationalizing its headcount following the post-COVID pullback in diagnostics and vaccine revenue. Genentech's commercial and research operations have also faced pressure as several of its major products face biosimilar competition.

Genentech occupies a specific place in the biotech world. It was one of the founding institutions of modern biotechnology, the company that demonstrated that molecular biology could produce medicines at commercial scale. The culture it built, the scientific rigor it institutionalized, and the commercial infrastructure it developed became the model for an entire industry. Working there, even in non-research roles, exposed you to standards of evidence, precision, and accountability that are rare in smaller biotech organizations.

The people being cut include researchers, clinical developers, regulatory professionals, and commercial operations leaders. All of them worked inside an environment that has produced more successful drugs than almost any organization in the history of biotechnology. That proximity to excellence, and the habits of rigor it builds, is exactly what the growing biotech ecosystem is trying to hire.

‍

The biotech industry is enormous, growing, and persistently short of experienced talent. Hundreds of companies are in various stages of drug development, and most of them have never done this before at the level Genentech operates. Former Genentech professionals are among the most credible advisors available to help them navigate that process.

R&D and clinical development professionals from Genentech advising biotech companies on trial design, regulatory strategy, and development planning typically bill $225 to $425 per hour. Regulatory affairs directors who have navigated FDA biologics applications, BLAs, biosimilar filings, label negotiations, are sought by every small and mid-size biotech approaching their first major regulatory interaction. Those engagements often run as project retainers in the range of $15,000 to $25,000 per month.

Medical affairs professionals with Genentech's oncology and immunology expertise are advising specialty pharma companies, payers, and healthcare systems on clinical evidence strategies and treatment guidelines. Commercial operations leaders from Genentech with biotech launch experience are in demand from pre-commercial companies preparing their first product launch, typically as fractional head of commercial or VP of commercial on a retainer basis.

‍

Genentech compensated its research and commercial professionals at among the highest levels in the biotech industry. Senior scientists and clinical development directors typically earned $190,000 to $340,000 in total compensation. Commercial and regulatory leaders often reached $280,000 to $450,000. The company's benefit package, South San Francisco location, and Roche parent organization provided additional stability that made the compensation package genuinely competitive.

To set a consulting rate: if your income target is $220,000 and your gross revenue goal is approximately $286,000 (adding 30 percent for taxes and benefits), divide by 1,000 billable hours for a target rate of $286 per hour. Round to $300 per hour, that is a credible, market-appropriate starting rate for Genentech-level biotech expertise. For narrow specialists in oncology clinical development, regulatory biologics, or rare disease, the market will support $350 to $450 from the start.

One practical note: biotech consulting engagements often begin as part-time project work and grow into more substantial retainer relationships as you prove value. Be open to starting with a defined project rather than insisting on a full retainer immediately. The relationship often converts.

‍

Genentech's name carries a specific weight in the biotech world that is different from any other company in the industry. It is not simply a large pharmaceutical company, it is the institution that established what rigorous biotech looks like. Saying you built your career there signals something specific to any informed buyer in the life sciences space.

The positioning challenge is being specific enough that buyers know exactly what problem you solve. "I help biotech companies design clinical development programs that give their molecules the best chance of regulatory success" is a statement that a CEO or CMO at a clinical-stage biotech will immediately understand and want to explore. "Former Genentech clinical development director" tells them where you worked. The outcome statement tells them what you do for them.

Your specific therapeutic area, oncology, immunology, neuroscience, rare disease, is a significant positioning asset because buyers typically want advisors who have worked in their specific disease space, not generalists. Lead with the therapeutic area, follow with the function, and anchor the whole thing in the outcomes you have seen achieved. The Genentech name will do the rest.

‍